NextCure and Avere to merge, targeting oral IL-23 therapy Jul 14, 2026 06:01AM
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy Jul 14, 2026 06:00AM
Form SCHEDULE 13G Akero Therapeutics, Inc. Filed by: WELLINGTON MANAGEMENT GROUP LLP Nov 12, 2025 09:34AM
Form SCHEDULE 13G/A Akero Therapeutics, Inc. Filed by: WELLINGTON MANAGEMENT GROUP LLP Aug 12, 2025 10:35AM
Form SCHEDULE 13G/A Akero Therapeutics, Inc. Filed by: WELLINGTON MANAGEMENT GROUP LLP May 12, 2025 10:46AM


Nov 8, 2024 10:53AM Form SC 13G/A Akero Therapeutics, Inc. Filed by: WELLINGTON MANAGEMENT GROUP LLP
Sep 9, 2024 09:10AM Form SC 13G/A Akero Therapeutics, Inc. Filed by: WELLINGTON MANAGEMENT GROUP LLP
Feb 8, 2024 10:06AM Form SC 13G Akero Therapeutics, Inc. Filed by: WELLINGTON MANAGEMENT GROUP LLP
Feb 6, 2023 02:44PM Form SC 13G/A Akero Therapeutics, Inc. Filed by: WELLINGTON MANAGEMENT GROUP LLP
Feb 4, 2022 09:13AM Form SC 13G Akero Therapeutics, Inc. Filed by: WELLINGTON MANAGEMENT GROUP LLP